Table 2.
Potential related metabolites and their metabolic pathways.
| VIP | Compounds | Formula | Retention time | Measured | Adducts type | M∗ | Fa# | B# | Related pathway |
|---|---|---|---|---|---|---|---|---|---|
| 1.26 | Galactonic acid | C6H1207 | 0.65 | 195.0505 | M-H | ↑ | ↓ | Pentose and glucuronate interconversions | |
| 2.11 | Pantothenic acid | C9H17N05 | 1.71 | 218.1029 | M-H | ↑ | ↓ | ↓ | Pantothenate and CoA biosynthesis |
| 2.13 | Orotidine | C10H13N2011P | 0.68 | 287.0516 | M-H,2M-H | ↑ | ↓ | ↓ | Pyrimidine metabolism |
| 1.02 | Orotic acid | C5H4N204 | 0.71 | 155.0094 | M-H | ↑ | ↓ | Pyrimidine metabolism | |
| 12.17 | Uric acid | C5H4N403 | 0.71 | 167.0207 | M-H, 2M-H | ↑ | ↓ | ↓ | Purine metabolism |
| 2.58 | Phenylpyruvic acid | C9H803 | 1.79 | 163.0397 | M-H | ↑ | ↓ | ↓ | Phenylalanine metabolism |
| 4.72 | Chenodeoxycholic acid | C02528 | 4.99 | 391.285 | M-H, 2M-H | ↓ | ↑ | ↑ | Bile secretion |
M: model group; N: normal group; Fa: CGT group; B: allopurinol group.
Variable importance in the projection (VIP) was obtained from the OPLS-DA model.
∗Compared with the N group, ∗p<0.05.
#Compared with the M group, #p<0.05. ↑, Relative increase in signal; ↓, relative decrease in signal.